Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase 2 study will evaluate 2 novel immunotherapy combinations in which
pembrolizumab is integrated with ramucirumab and paclitaxel in patients with advanced gastric
and GEJ adenocarcinoma. A total of 58 patients will be enrolled to the study. Each arm will
have 26 patients. Although the study has a randomized design, patients in both arms will
receive study drug (pembrolizumab).